Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

A global research priority agenda to advance public health responses to fatty liver disease
Jeffrey V. Lazarus, Henry E. Mark, Alina M. Allen, et al.
Journal of Hepatology (2023) Vol. 79, Iss. 3, pp. 618-634
Open Access | Times Cited: 69

Showing 1-25 of 69 citing articles:

Critical appraisal of metabolic dysfunction-associated steatotic liver disease: Implication of Janus-faced modernity
Gi‐Ae Kim, Joon Ho Moon, Won Kim
Clinical and Molecular Hepatology (2023) Vol. 29, Iss. 4, pp. 831-843
Open Access | Times Cited: 67
Steatotic liver disease
Mads Israelsen, Sven Francque, Emmanuel Tsochatzis, et al.
The Lancet (2024) Vol. 404, Iss. 10464, pp. 1761-1778
Closed Access | Times Cited: 30
Disparities in metabolic dysfunction-associated steatotic liver disease and cardiometabolic conditions in low and lower middle-income countries: a systematic analysis from the global burden of disease study 2019
Pojsakorn Danpanichkul, Kanokphong Suparan, Priyata Dutta, et al.
Metabolism (2024) Vol. 158, pp. 155958-155958
Closed Access | Times Cited: 29
Opportunities and challenges following approval of resmetirom for MASH liver disease
Jeffrey V. Lazarus, Dana Ivancovsky‐Wajcman, Henry E. Mark, et al.
Nature Medicine (2024) Vol. 30, Iss. 12, pp. 3402-3405
Closed Access | Times Cited: 24
The future of International Classification of Diseases coding in steatotic liver disease: An expert panel Delphi consensus statement
Hannes Hagström, Leon A. Adams, Alina M. Allen, et al.
Hepatology Communications (2024) Vol. 8, Iss. 2
Open Access | Times Cited: 22
Incidence of liver cancer in young adults according to the Global Burden of Disease database 2019
Pojsakorn Danpanichkul, Majd B. Aboona, Banthoon Sukphutanan, et al.
Hepatology (2024) Vol. 80, Iss. 4, pp. 828-843
Closed Access | Times Cited: 21
Integrative clinical and preclinical studies identify FerroTerminator1 as a potent therapeutic drug for MASH
Liang Tao, Xinquan Yang, Chaodong Ge, et al.
Cell Metabolism (2024) Vol. 36, Iss. 10, pp. 2190-2206.e5
Open Access | Times Cited: 20
Guideline for the Prevention and Treatment of Metabolic Dysfunction-associated Fatty Liver Disease (Version 2024)
Jian‐Gao Fan, Xiaoyuan Xu, Rui-Xu Yang, et al.
Journal of Clinical and Translational Hepatology (2024) Vol. 000, Iss. 000, pp. 000-000
Open Access | Times Cited: 16
Alcohol–Related Liver Disease, Followed by Metabolic Dysfunction–Associated Steatotic Liver Disease, Emerges as the Fastest‐Growing Aetiologies for Primary Liver Cancer in the United States
Pojsakorn Danpanichkul, Kwanjit Duangsonk, Markos Kalligeros, et al.
Alimentary Pharmacology & Therapeutics (2025)
Closed Access | Times Cited: 4
Metabolic dysfunction-associated steatotic liver disease in adults
Daniel Q. Huang, Vincent Wai‐Sun Wong, Mary E. Rinella, et al.
Nature Reviews Disease Primers (2025) Vol. 11, Iss. 1
Closed Access | Times Cited: 2
Steatotic Liver Disease: Metabolic Dysfunction, Alcohol, or Both?
Katharina Staufer, Rudolf Stauber
Biomedicines (2023) Vol. 11, Iss. 8, pp. 2108-2108
Open Access | Times Cited: 38
The Impact of Stigma on Quality of Life and Liver Disease Burden Among Patients with Nonalcoholic Fatty Liver Disease
Zobair M. Younossi, Saleh A. Alqahtani, Jesús Funuyet‐Salas, et al.
JHEP Reports (2024) Vol. 6, Iss. 7, pp. 101066-101066
Open Access | Times Cited: 15
Envisioning how to advance the MASH field
Alina M. Allen, Zobair M. Younossi, Anna Mae Diehl, et al.
Nature Reviews Gastroenterology & Hepatology (2024)
Closed Access | Times Cited: 13
MOVING DIAGNOSIS OF LIVER FIBROSIS INTO THE COMMUNITY
Elisa Pose, Salvatore Piano, Maja Thiele, et al.
Journal of Hepatology (2025)
Closed Access | Times Cited: 1
Psychosocial risks in Metabolic dysfunction-associated steatotic liver disease
Hanne Åström, Christine Takami Lageborn, Hannes Hagström
Expert Review of Gastroenterology & Hepatology (2025)
Closed Access | Times Cited: 1
Food inequity and insecurity and MASLD: burden, challenges, and interventions
Shira Zelber‐Sagi, Patrizia Carrieri, Juan M. Pericàs, et al.
Nature Reviews Gastroenterology & Hepatology (2024) Vol. 21, Iss. 10, pp. 668-686
Closed Access | Times Cited: 8
Disparities in steatosis prevalence in the United States by Race or Ethnicity according to the 2023 criteria
Luis Antonio Díaz, Jeffrey V. Lazarus, Eduardo Fuentes‐López, et al.
Communications Medicine (2024) Vol. 4, Iss. 1
Open Access | Times Cited: 8
Machine Learning-Based Assessment of Survival and Risk Factors in Non-Alcoholic Fatty Liver Disease-Related Hepatocellular Carcinoma for Optimized Patient Management
Miguel Suárez, Sergio Gil-Rojas, Pablo Martínez-Blanco, et al.
Cancers (2024) Vol. 16, Iss. 6, pp. 1114-1114
Open Access | Times Cited: 6
A narrative review of lifestyle management guidelines for metabolic dysfunction-associated steatotic liver disease
Dana Ivancovsky‐Wajcman, Christopher J. Byrne, John Dillon, et al.
Hepatology (2024)
Open Access | Times Cited: 6
Trends in Oxidative Balance Score and Prevalence of Metabolic Dysfunction-Associated Steatotic Liver Disease in the United States: National Health and Nutrition Examination Survey 2001 to 2018
Zongbiao Tan, Yanrui Wu, Yang Meng, et al.
Nutrients (2023) Vol. 15, Iss. 23, pp. 4931-4931
Open Access | Times Cited: 14
MASLD emerging from the fog of fatty liver
Giulio Marchesini, Roberto Vettor, Massimo Pinzani
Journal of Hepatology (2023) Vol. 80, Iss. 2, pp. 178-180
Open Access | Times Cited: 14
Health information in short videos about metabolic dysfunction‐associated steatotic liver disease: Analysing quality and reliability
Ruihao Ding, Qingzhou Kong, Longfei Sun, et al.
Liver International (2024) Vol. 44, Iss. 6, pp. 1373-1382
Closed Access | Times Cited: 5
A narrative review about cognitive impairment in Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD): Another matter to face through a holistic approach
Marica Meroni, Miriam Longo, Erika Paolini, et al.
Journal of Advanced Research (2024) Vol. 68, pp. 231-240
Open Access | Times Cited: 5
Use of non‐invasive diagnostic tools for metabolic dysfunction‐associated steatohepatitis: A qualitative exploration of challenges and barriers
Emmanuel Tsochatzis, Luca Valenti, Maja Thiele, et al.
Liver International (2024) Vol. 44, Iss. 8, pp. 1990-2001
Closed Access | Times Cited: 5
It is time to expand the fatty liver disease community of practice
Jeffrey V. Lazarus, Christopher J. Kopka, Zobair M. Younossi, et al.
Hepatology (2023) Vol. 78, Iss. 5, pp. 1325-1328
Open Access | Times Cited: 12
Page 1 - Next Page

Scroll to top